Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects.

Thromb Haemost

Bernd Jilma, MD, Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria, Tel.: +43 1 40400 29900, Fax: +43 1 40400 29980, E-mail:

Published: June 2015

Download full-text PDF

Source
http://dx.doi.org/10.1160/TH15-04-0324DOI Listing

Publication Analysis

Top Keywords

development specific
4
specific antidotes
4
antidotes idarucizumab
4
idarucizumab reversal
4
reversal dabigatran
4
dabigatran effects
4
development
1
antidotes
1
idarucizumab
1
reversal
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!